Table 3 TP53 mutation and allelism (n = 211)
| Â | No mutation | Mutation on Arg | Mutation on Pro | P value |
|---|---|---|---|---|
Case, n (%) | 64 (30.3) | 93 (44.1) | 54 (25.6) | Â |
Primary tumor location, n (%) | Â | Â | Â | Â |
   Colon | 35 (31.0) | 51 (45.1) | 27 (23.9) |  |
   Rectum | 29 (29.6) | 42 (42.9) | 27 (27.6) | 0.832 |
Site, n (%) | Â | Â | Â | Â |
   Proximal | 18 (36.7) | 17 (34.7) | 14 (28.6) |  |
   Distal | 17 (26.6) | 34 (53.1) | 13 (20.3) | 0.149 |
Histopathological grade, n (%) | Â | Â | Â | Â |
   G1+G2 | 50 (28.1) | 79 (44.4) | 49 (27.5) |  |
   G3 | 14 (42.4) | 14 (42.4) | 5 (15.2) | 0.167 |
Lymph node metastasis, n (%) | Â | Â | Â | Â |
   N0 | 43 (40.6) | 39 (36.8) | 24 (22.6) |  |
   N1 | 16 (19.0) | 45 (53.6) | 23 (27.4) |  |
   N2 | 5 (23.8) | 9 (42.9) | 7 (33.3) | 0.022* |
Dukes' stage, n (%) | Â | Â | Â | Â |
   A | 19 (45.2) | 15 (35.7) | 8 (19.0) |  |
   B | 23 (38.3) | 21 (35.0) | 16 (26.7) |  |
   C | 12 (16.0) | 42 (56.0) | 21 (28.0) |  |
   D | 10 (29.4) | 15 (44.1) | 9 (26.5) | 0.024* |